pemafibrate
Small moleculeexperimental
Pemafibrate, sold under the brand name Parmodia, is a peroxisome proliferator-activated receptor alpha (PPARα) agonist. It is developed and marketed by Kowa Pharmaceuticals. — Wikipedia
Clinical trial activity
15 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
7
Phase 2
8
Phase 3
4
Phase 4
0
Earliest trial started Jan 1, 2016 (NCT02650076)
Timeline
Indications
Studied for
- Diabetic Retinopathy · Phase 3
- Dyslipidemias · Phase 3
- Healthy Volunteers · Phase 1
- Hyperlipidemias · Phase 3
- Lipoproteins · Phase 2
- Liver Cirrhosis · Phase 1
- Liver Cirrhosis, Biliary · Phase 2
- Macular Edema · Phase 3
- Non-alcoholic Fatty Liver Disease · Phase 2
- Pruritus · Phase 2
- Renal Insufficiency · Phase 1
Mechanism of action
Peroxisome proliferator-activated receptor alpha agonist
- Unspecified targetUnclear
unclear
Chemistry & pharmacology
Loading structure…
SMILES
CC[C@@H](Oc1cccc(CN(CCCOc2ccc(OC)cc2)c2nc3ccccc3o2)c1)C(=O)O- Mol. weight
- 490.56 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
Oral
Yes
Parenteral
No
Topical
No
Sources
- WikipediaPemafibrate ↗
- ChEMBLCHEMBL247951 ↗
Also known as
- pemafibrate
- sk-1405
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06525311 | Phase 1 | Oct 1, 2024 | Kowa |
| NCT06342596 | Phase 1 | Mar 5, 2024 | Eli Lilly |
| NCT06247735 | Phase 2 | Feb 7, 2024 | Kowa |
| NCT05778864 | Phase 1 | Mar 17, 2023 | Eli Lilly |
| NCT05563246 | Phase 2 | Nov 24, 2022 | Eli Lilly |
| NCT05038787 | Phase 1 | Nov 11, 2021 | Eli Lilly |
| NCT04998981 | Phase 3 | Sep 17, 2021 | Kowa |
| NCT04714151 | Phase 3 | Feb 1, 2021 | Kowa |
| NCT04716595 | Phase 3 | Feb 1, 2021 | Kowa |
| NCT06623539 | Phase 2 | Dec 23, 2020 | Yokohama City University |
| NCT04472676 | Phase 1 | Aug 18, 2020 | Eli Lilly |
| NCT03345901 | Phase 3 | Jan 15, 2018 | Jaeb Center for Health Research, Kowa, National Eye Institute (NEI) |
| NCT03218501 | Phase 2 | Aug 28, 2017 | Sanwa Kagaku Kenkyusho Co., Ltd. |
| NCT02846181 | Phase 1 | Jul 1, 2016 | Sanwa Kagaku Kenkyusho Co., Ltd. |
| NCT02650076 | Phase 1 | Jan 1, 2016 | Sanwa Kagaku Kenkyusho Co., Ltd. |
Showing 15 of 15 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Kowa | For profit | 6 | 5 | 3 | 2018 |
| Eli Lilly | For profit | 5 | 5 | 2 | 2020 |
| Sanwa Kagaku Kenkyusho Co., Ltd. | For profit | 3 | 3 | 2 | 2016 |
| Jaeb Center for Health Research | Academic/Hospital | 1 | 1 | 1 | 2018 |
| National Eye Institute (NEI) | Government | 1 | 0 | 1 | 2018 |
| Yokohama City University | Academic/Hospital | 1 | 1 | 1 | 2020 |
6 organizations
Page 1 / 1